Reviewed by a GPhC-registered Pharmacist at Newdays Pharmacy | Published: 2026 | Book an appointment
| Quick Answer: Polycystic ovary syndrome (PCOS) is strongly associated with insulin resistance and obesity, making weight management particularly challenging for affected women. GLP-1 and dual GIP/GLP-1 receptor agonists such as Mounjaro and Wegovy are not specifically licensed for PCOS, but emerging evidence and clinical practice support their use in women with PCOS and obesity who meet standard eligibility criteria. A clinical assessment is required. |
Polycystic ovary syndrome affects approximately one in ten women of reproductive age in the UK and is one of the most common endocrine conditions presented at Newdays Pharmacy in Berkshire. Weight management is central to PCOS management for many affected women, both for reproductive health and for reducing long term metabolic risk. But PCOS makes weight loss harder than it is for women without the condition, and understanding why, and what evidence based options exist, is important.
Why PCOS Makes Weight Management More Difficult
PCOS is characterised by insulin resistance in a significant proportion of affected women, even those with a normal BMI. Insulin resistance means the body requires higher insulin levels to manage blood glucose, and elevated insulin promotes fat storage particularly in the abdominal region, drives hunger, and impairs the body’s ability to lose weight through standard caloric restriction alone.
In addition, elevated androgens (male hormones) in PCOS can alter fat distribution toward central adiposity, which is metabolically harmful and particularly difficult to lose. Disrupted sleep from PCOS related conditions and the psychological burden of the condition, including anxiety and depression, which are significantly more prevalent in women with PCOS, further impair weight management efforts.
What Role Can GLP-1 and dual GIP/GLP-1 Medication Play in PCOS?
GLP-1 and dual GIP/GLP-1 receptor agonists address several of the underlying mechanisms that make weight management difficult in PCOS. By improving insulin sensitivity and reducing fasting insulin levels, they address one of the core metabolic drivers. By reducing appetite and promoting satiety, they overcome some of the hormonally driven food seeking behaviour that makes caloric restriction difficult. By promoting preferential reduction in visceral adipose tissue, they target the most metabolically harmful fat depot.
Clinical trial subgroup analyses and smaller dedicated PCOS studies have shown that GLP-1 and dual GIP/GLP-1 therapy produces meaningful weight loss in women with PCOS and improves menstrual regularity, androgen levels, and insulin sensitivity. Semaglutide in particular has been assessed in PCOS populations with promising results, though none of these medicines are specifically licensed for PCOS as an indication.
Metformin and PCOS: An Important Context
Metformin is widely used in PCOS management, both for its insulin sensitising effects and for its modest weight neutral or weight reducing properties. For women with PCOS who have not already tried metformin, it is often a first line consideration. GLP-1 and dual GIP/GLP-1 medication and metformin can be used together in some clinical contexts; your prescriber will assess whether a combination approach is appropriate.
| Book Now: Book a Travel Health Consultation or Weight Management Appointment. We serve patients from Windsor, Eton, Twyford, Reading, and across Berkshire and Buckinghamshire. |
Frequently Asked Questions
Mounjaro is not licensed specifically to treat PCOS. However, women with PCOS who meet the standard eligibility criteria for weight management, such as a BMI of 30 or above, or 27 or above with a weight-related medical condition, may be assessed for Mounjaro or Wegovy through our weight management service. Book a consultation at Newdays Pharmacy for a full clinical assessment.
Yes. Losing weight can significantly improve PCOS symptoms. Even a modest weight loss of 5–10% of body weight has been shown to improve menstrual regularity, reduce excess androgen levels, improve fertility, decrease insulin resistance, and lower the long-term risk of type 2 diabetes and cardiovascular disease.
The most appropriate treatment depends on your individual health, BMI, symptoms and treatment goals. Metformin is commonly used to improve insulin resistance in PCOS, while Mounjaro and other GLP-1-based medicines can achieve greater weight loss in eligible patients with obesity. Your prescriber will recommend the option that best suits your clinical needs.
| Clinical Disclaimer: This article is intended for general information only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment or medication. Information is accurate as of the date of publication and reviewed by a GPhC-registered pharmacist. Newdays Pharmacy is registered with the General Pharmaceutical Council (GPhC). Branch registration numbers: Eton/Windsor 1029048 | Twyford 1028983 | Coley Park Reading 1029008. |